Description

Retatrutide 5 mg is a research-grade formulation of the investigational weight-management peptide currently in Phase 3 trials. While official clinical studies focus on doses up to 12 mg weekly, the 5 mg strength is offered by compounding and research suppliers as an intermediate option.

Like other Retatrutide doses, 5 mg works as a triple agonist (GLP-1, GIP, and glucagon receptors), designed to support:

• Significant weight reduction

• Improved metabolic balance

• Better glucose control in obesity and Type 2 diabetes

This dosage is often positioned between the low-dose titration phases (2–4 mg) and higher therapeutic doses (8–12 mg).